Group items tagged

Liver transplantation is a life-saving procedure that can significantly improve the quality of life for individuals with end-stage liver disease or liver failure.

If you do not have the disease called diabetes, then be happy and be sure to do all you can to prevent it. For prevention of diabetes is better than the cure. The symptoms of diabetes are many and vary. At the earliest stage, diabetes does not show any symptom. In many case, the disease is diagnosed accidentally when undergoing check-up for other complaints...

Parents often feel that teaching a toddler to brush his teeth is quite early and can wait. But this is completely incorrect. Oral hygiene is essential in all stages of life as it can lead to serious infections and diseases.

As the need for physicians around the country rises and physicians struggle to shoulder an increasing mountain of student debt while maintaining a semblance of work-life balance, locums has become a viable route for success.

As per the Ayurveda, paralysis treatment includes a balance of herbal medications, Ayurvedic massages, and lifestyle changes. We at Parijatak incorporate the same at each stage of our paralysis treatment in Ayurveda to ensure effective outcomes and quick recovery. Under the expertise of several therapists, we work out the best initiatives to give paralysis Ayurvedic cure a completely new form.

Burnout is a serious problem afflicting not only attending physicians, but also medical trainees at all stages of the training process.

The National Institute for Health and Care Excellence (NICE) today issued a draft guidance recommending dapagliflozin, sold under the brand name Forxiga among others, as an option for treating certain adults with chronic kidney disease (CKD). Dapagliflozin belongs to a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors. It is the first SGLT2 inhibitor to be recommended through NICE's technology appraisal process for CKD. Adding dapagliflozin to current standard care has been shown to significantly reduce the risk of having declining kidney function, end-stage kidney disease, or dying from causes related to the kidneys or cardiovascular system. "Dapagliflozin is a promising treatment for certain people with chronic kidney disease and it has the potential to increase the length of time before the disease gets worse," Meindert Boysen, deputy chief executive and director of the NICE Centre for Health Technology Evaluation, said.

Indian pharmaceutical companies are gearing up to become global suppliers of repurposed Covid-19 drugs. With the launch of new innovative Covid-19 oral drugs, Indian companies are again expected to grab opportunities in the global supply of oral Covid-19 drugs, according to data and analytics company GlobalData. As several countries witness increasing cases of Covid-19 despite vaccination, they have started booking supply orders for innovative Covid-19 treatments like antibody cocktails, monoclonal antibodies and the latest addition such Merck's the oral Covid-19 drug 'molnupiravir'. Prashant Khadayate, pharma analyst at GlobalData, comments: "Oral treatment for Covid-19 would be the most convenient option for the patients ranging from mild to moderate Covid-19 and would not require a hospital setting. Currently, a majority of the Covid-19 treatments require a hospital setting." According to GlobalData's Pharma Intelligence Center, the UK is the first country to approve molnupiravir which is in pre-registration stage in the US, EU and Japan.

A news report suggests the Department of Health and Social Care is aiming to be ready to start charging for Covid-19 tests which are currently free at the end of June. Britain has been increasingly dependent on rapid testing to try to tackle the more-transmissible Omicron variant, which has spread rapidly through the population but is less severe. The government has previously said it will end the universal free provision of easy-to-use lateral flow devices (LFDs) at a "later stage", with individuals and businesses bearing the cost. The Department of Health has declined to say what the tests cost, citing commercial contracts. One source has told the Reuters news agency they can run to £30 for a pack of seven. Free pick up from pharmacies The tests have been made freely available to order online or pick up from local pharmacies since April. The UK Health Security Agency said that between December 30 and January 5 more than 8 million LFDs were conducted, the highest weekly figure on record.

Britain on Tuesday (January 4) faced warnings of an impending hospital crisis due to staff shortages caused by a wave of Omicron infections, as the country returned to work after Christmas. However, Britain's vaccine minister said hospitalised Covid-19 patients were showing less severe symptoms than before, adding that there was no need for further restrictions at this stage. Prime minister Boris Johnson resisted imposing stringent lockdown measures in England ahead of New Year as Omicron fuelled a spike in cases to record highs. While hospitalisations are rising they have not tracked the trajectory of daily cases, possibly reflecting the impact of vaccines and booster shots, the likely lower severity of Omicron and the time lag in people going into hospital. "At the moment, if you look at the people who have been hospitalised, they are going in with less severe conditions than before," minister for Vaccines and Public Health Maggie Throup told Sky News, adding that the "Plan B" Johnson brought in in December was working. "The numbers that are in hospital beds is about half what it was a year ago - and that just shows the power of the vaccine."

Walgreens Boots Alliance, the parent company of Boots UK, has begun a strategic review of its business in the United Kingdom, chief executive officer Rosalind Brewer said on Tuesday (January 11) - as the pharmacy chain tries to renew its focus on US healthcare. Boots has over 2,200 stores across the UK, which include pharmacies, health and beauty stores, among others, according to the chain's website. "This review is very much in line with our renewed priorities and strategic direction. In particular, our increased focus on US healthcare. While the process is at an exploratory stage, we do expect to move quickly," Brewer said at the JP Morgan Healthcare Conference. The review comes at a time when the company, which was formed in 2014 after the acquisition of stake in Alliance Boots by Walgreens, moves beyond its drugstores with its investments in two smaller healthcare providers, CareCentrix and VillageMD.

Arrowhead Pharmaceuticals on Monday (November 22) entered a drug development deal with GlaxoSmithKline (GSK) under which the British drugmaker will develop and market Arrowhead's potential treatment for patients with fatty liver disease NASH. Under the pact, Arrowhead said it would get an upfront payment of $120 million and is eligible for additional milestone payments including up to $190 million at first commercial sale of the product, and up to $590 million in sales-related milestone payments. The drug candidate, ARO-HSD, is currently in an early-to-mid stage trial for nonalcoholic steatohepatitis (NASH), a fatty liver disease. It is based on RNA interference technology, where genes that contribute to disease are silenced.

British drugmaker GSK said on Tuesday (December 7) its antibody-based Covid-19 therapy with US partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies. The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement. Last week, another pre-clinical data showed that the drug had worked against key mutations of the Omicron variant. Sotrovimab is designed to latch on to the spike protein on the surface of the coronavirus, but Omicron has been found to have an unusually high number of mutations on that protein. "These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO," GSK chief scientific officer Hal Barron said.

The General Pharmaceutical Council (GPhC) today decided to convene a new group, involving all the key stakeholders, focused on assurance of practice post-registration. The decision in today's (9 December) council meeting follows the recommendation of a working group chaired by council member and pharmacist Aamer Safdar on the role of the regulator in post-registration education and training. The new group will be tasked with articulating a set of guiding principles where patient safety is the overarching priority, after carrying out a horizon scanning exercise to pull together an understanding of the system wide approach currently in place. The working group noted that the wider approach, in relation to regulation of post-registration practice and not simply education and training, may require the GPhC reviewing and developing its own control measures, and involving patients and the public in the next stages of work. Reviewing the work on online pharmacy services, the council meeting supported the regulator's plans to continue to require pharmacy websites to be arranged so that a person cannot choose a prescription only medicine and its quantity before there has been an appropriate consultation with a prescriber.

Wegovy maker Novo Nordisk said on Tuesday (Aug 8) a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit, boosting the Danish company's hopes of moving beyond its image as a lifestyle drug. The increasingly popular Wegovy has transformed the weight-loss market since its U.S. launch in June 2021, capturing the attention of patients, investors and celebrities worldwide. Novo's news lifted shares in Europe's second-most valuable listed company after LVMH by more than 17 per cent to record highs. They have now surged almost 165 per cent over the past two years. The results of the late-stage trial may help persuade insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy, which is $1,300 a month in the United States, for a wider range of patients. U.S. law classifies weight-loss treatments as lifestyle drugs and bars the Medicare health plan for older Americans from covering them and experts said the new data could lead the U.S. government to reassess that.

Chair of the Health and Social Care Committee Steve Brine MP has called on community pharmacy contractors to join a newly launched a parliamentary 'call for evidence' which will look into 'prevention' as a key to the future of the NHS. A former pharmacy minister and keen supporter of the sector, Mr Brine has called on all community pharmacists to "make their contribution count" by taking part in a major inquiry which will remain open for submission until Wednesday 8 February 2023 and will also involve general practitioners, nurses and other health professionals. Community pharmacists can submit their proposals written under 750 words, outlining what they think are the issues around prevention the parliamentary body should explore, why these issues deserve the Commons Select Committee's attention, and how government policy could be developed or improved to address them. The submissions will then be used to help the committee decide where it should focus its attention in the later stages of the inquiry on prevention, which is a vital part of the NHS Long Term Plan.

Amgen's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday (December 3). The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%. At 150 days after the last dose, maintained weight loss had dropped to 11.2% below original weight at the start of the trial, according to findings detailed at a meeting of World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease in Los Angeles. Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said.

A total of 525 candidates have passed the common registration assessment for pharmacists held in November, the regulators GPhC and PSNI have announced on Tuesday. With 937 candidates sitting for the registration assessment, held jointly by the General Pharmaceutical Council (GPhC) and Pharmaceutical Society of Northern Ireland (PSNI) on 3 November, the pass rate was 56 per cent, down from the 61 per cent for the Autumn 2021. Among the GPhC candidates, 59 per cent were sitting for the first time, 30 per cent for the second time and 8 per cent for the third time. (The break-up was not available for the 3 per cent PSNI candidates.) In comparison, for the June sitting 89 per cent of candidates were sitting for the first time, 7 per cent were sitting for the second time and 4 per cent were sitting for the third time. "We would like to congratulate the successful candidates and we look forward to them joining our register and continuing to the next stage of their career," Duncan Rudkin, GPhC chief executive said.

The embryo is the combined form of a matured egg and sperm. It is generally known as the most critical stage of IVF treatment. Despite that, successful embryo implantation only decides the achievement of pregnancy, and when it fails, it obstructs the entire IVF process. It extensively occurs when a couple fails to develop a healthy embryo using their eggs and sperm because of poor health conditions.